Abstract
Dysfunction of peripheral nerves due to metabolic, toxic, infectious, or genetic causes is a common and debilitating syndrome resulting in sensory loss. Peripheral neuropathies are one of the most widespread neurological disorders, affecting nearly 20 million people in the United States alone. Pharmacologic treatment for peripheral neuropathies is one of the most challenging fields in the clinical research. Sensory neurons are widely distributed and relatively inaccessible to direct drug delivery. Targeted delivery of neurotrophic factors to the primary sensory afferent for treatment of polyneuropathy by gene transfer approach offers the possibility of a highly selective targeted release of bioactive molecules within the nervous system. Preclinical studies with non-replicating herpes simplex virus (HSV)-based vectors injected into the skin to transduce neurons in the dorsal root ganglion (DRG) have demonstrated efficacy in preventing progression of sensory neuropathy without any possible systemic side effects.
Keywords: Diabetes, DRG, gene therapy, growth factors, HSV, peripheral neuropathy.
Current Gene Therapy
Title:Targeted Delivery of Growth Factors by HSV-Mediated Gene Transfer for Peripheral Neuropathy
Volume: 13 Issue: 5
Author(s): Munmun Chattopadhyay
Affiliation:
Keywords: Diabetes, DRG, gene therapy, growth factors, HSV, peripheral neuropathy.
Abstract: Dysfunction of peripheral nerves due to metabolic, toxic, infectious, or genetic causes is a common and debilitating syndrome resulting in sensory loss. Peripheral neuropathies are one of the most widespread neurological disorders, affecting nearly 20 million people in the United States alone. Pharmacologic treatment for peripheral neuropathies is one of the most challenging fields in the clinical research. Sensory neurons are widely distributed and relatively inaccessible to direct drug delivery. Targeted delivery of neurotrophic factors to the primary sensory afferent for treatment of polyneuropathy by gene transfer approach offers the possibility of a highly selective targeted release of bioactive molecules within the nervous system. Preclinical studies with non-replicating herpes simplex virus (HSV)-based vectors injected into the skin to transduce neurons in the dorsal root ganglion (DRG) have demonstrated efficacy in preventing progression of sensory neuropathy without any possible systemic side effects.
Export Options
About this article
Cite this article as:
Chattopadhyay Munmun, Targeted Delivery of Growth Factors by HSV-Mediated Gene Transfer for Peripheral Neuropathy, Current Gene Therapy 2013; 13 (5) . https://dx.doi.org/10.2174/156652321305131212123237
DOI https://dx.doi.org/10.2174/156652321305131212123237 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Advances in the Treatment of Alzheimer's Disease: Present and Future
Current Drug Therapy Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology Platelets in Rheumatic Diseases: Friend or Foe?
Current Pharmaceutical Design Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Leptin and Vascular Smooth Muscle Cells
Current Pharmaceutical Design The Role of Autophagy in Rheumatic Disease
Current Drug Targets Cerebrovascular Diseases in HIV-Infected Patients
Current HIV Research Editorial [Hot Topic: Clinical Trials in ANCA Associated Vasculitis (Guest Editor: Chetan Mukhtyar)]
Current Immunology Reviews (Discontinued) Editorial (Thematic Issue: Cell Immunity in Cardiovascular and Cerebrovascular Diseases)
Current Immunology Reviews (Discontinued) Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
Current Pharmaceutical Design Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Editorial:
Current Immunology Reviews (Discontinued) Proinflammatory Activities of Leptin in Non-Autoimmune Conditions
Inflammation & Allergy - Drug Targets (Discontinued) Niemann-Pick C1-Like 1 (NPC1L1) Inhibition and Cardiovascular Diseases
Current Medicinal Chemistry Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Adenosine Receptors: What We Know and What We are Learning
Current Topics in Medicinal Chemistry Effect of an Angiotensin II Receptor Blocker and Two Angiotensin Converting Enzyme Inhibitors on Transforming Growth Factor-β (TGF-β) and α-Actomyosin (α SMA), Important Mediators of Radiation-Induced Pneumopathy and Lung Fibrosis
Current Pharmaceutical Design